#HUPO2026 is an exciting showcase of the latest proteomics technologies. This year NULISA is featured in several posters and sessions. Visit us at our booth 246 and attend the posters and sessions to explore how Precision Proteomics is impacting health and disease research. Also, don't miss our Industry Lunch Seminar, Tuesday, 29 Sept at 12:15 in Nicoll 1 with Dr. Steve Williams (Alamar Bio), Dr. Mitchell K.P. Lai (National University Health Center, Singapore) and Dr. Yuanbing Jiang (HKUST).

Just published! The first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. Researchers at Washington University School of Medicine in St. Louis used Alamar's NULISAseq™ CNS 120 Panel to analyze more than 2,300 plasma samples, finding that biomarkers associated with amyloid clearance differed from those associated with cognitive decline in patients receiving lecanemab. By measuring brain-derived tau alongside more than 100 additional proteins, investigators were able to track pathology and treatment response in a single assay, uncovering biological changes that may be missed when evaluating only a small number of biomarkers. As anti-amyloid therapies become part of routine care, precision proteomics is opening a new window into researching how patients respond to treatment. Read the full press release: na2.hubs.ly/H080hnS0 #PrecisionProteomics #AlzheimersResearch #Biomarkers #Neuroscience #NULISA

⏰ Coming up tomorrow: Rethinking ALS Biomarkers   There’s still time to register for a closer look at how ultra-sensitive proteomics is advancing ALS research.   Hear from Prof. Alberto Catanese (RWTH Aachen University) and Clare Paterson, PhD (Alamar Biosciences) as they explore emerging insights into ALS biology and the potential of high-sensitivity protein detection to uncover biomarkers that have historically been difficult to measure.   Tune in tomorrow to explore the latest ALS biomarker research, followed by a live Q&A with the speakers.   👉 Register now: na2.hubs.ly/H07ZTgg0

🕛 Happening Tomorrow: IMID Webinar   Don’t miss the opportunity to hear emerging research and biomarker insights across immune-mediated inflammatory diseases (IMIDs).   Join Dr. Chris Wincup (King’s College London), Dr. Felix Wohlrab (Charité – Universitätsmedizin Berlin), and Dr. Jasmine Sim (Newcastle University) as they share new findings generated using NULISA™ technology across multiple IMID indications.   Discover what ultra-sensitive proteomics is revealing about disease biology and shared inflammatory pathways in tomorrow's webinar, then join the conversation during a live expert panel discussion.   🗓️ Thursday, September 24 ⏰ 3:00–5:30 PM BST   Register now: na2.hubs.ly/H07ZTfq0   #Immunology #AutoimmuneDisease #Inflammation #IMID #MultipleSclerosis #IBD #RheumatoidArthritis #Lupus #Asthma

Today is World Alzheimer’s Day 🧠 More than 55 million people worldwide are living with dementia, including over 7 million Americans living with Alzheimer’s disease. At Alamar Biosciences, we recognize the importance of advancing research that deepens our understanding of neurodegenerative disease and helps move the field toward earlier detection and better outcomes. This #WorldAlzheimersDay, we join the global community in raising awareness and supporting everyone impacted by Alzheimer’s and other dementias. Learn more about these tips from the @alzassociation: 10 Early Signs and Symptoms of Alzheimer’s & Dementia: bit.ly/3V54niD Ways to Support Brain Health: bit.ly/4hkuERi #WorldAlzheimersDay #AlzheimersAwareness #AlzheimersResearch #Neuroscience #Proteomics

📍 Singapore, we're coming to HUPO 2026!   Experience what high-sensitivity, multiplex proteomics can unlock at the 2026 HUPO World Congress, the premier international gathering for the global proteomics community. Connect with us at Booth 246 to see the NULISA™ and ARGO® HT platforms in action and learn how they can accelerate your research.   Join us on Sept 29 for our Industry Lunch Symposium featuring Steve Williams (Alamar Biosciences), Mitchell K.P. Lai (National University Health System, Singapore), and Yuanbing Jiang (The Hong Kong University of Science & Technology) presenting new data on plasma proteomics applications in Alzheimer's disease and dementia research.   🗓 Tuesday, September 29 ⏰ 12:15–1:15 PM SGT 📍 Nicoll 1   👉 Learn more: na2.hubs.ly/H07StkB0   #NULISA #HUPO2026 #Proteomics #BiomarkerDiscovery #PrecisionMedicine

🔬 What can ultra-sensitive proteomics reveal about immune-mediated inflammatory diseases?   Join Dr. Chris Wincup (King’s College London), Dr. Felix Wohlrab (Charité – Universitätsmedizin Berlin), and Dr. Jasmine Sim (Newcastle University) for an upcoming webinar exploring emerging biomarker insights across lupus, neuromyelitis optica spectrum disease (NMOSD), and rheumatoid arthritis using ultra-sensitive NULISA™ technology.   Hear new findings, gain insight into shared biological and inflammatory pathways across diseases, and discover how highly multiplexed protein profiling is helping uncover biology that was previously difficult to detect.   Don’t miss the latest insights shaping IMID biomarker research.    Register now to join the discussion: na2.hubs.ly/H07Q3Vl0… (na2.hubs.ly/H07Q40c0)

Our NULISA™ Certified Service Provider network continues to grow! 🎉   We’re pleased to introduce attyloid as our newest Certified Service Provider, expanding access to NULISA™ technology and expertise for the biopharma research community.   attyloid is a specialized bioanalytical CRO providing ultrasensitive biomarker services for preclinical and clinical research. Combining NULISA™ technology with extensive translational biomarker expertise, their team supports biopharma partners across disease areas—from study design through scientific data interpretation.   We look forward to seeing how attyloid helps researchers leverage ultrasensitive biomarker analysis to advance their studies.   Learn more about attyloid: Ultra-sensitive CNS biomarker profiling | NULISA (na2.hubs.ly/H07PxbH0) Explore our CSP network: Alamar Certified Service Providers | Protein Biomarker Assays (na2.hubs.ly/H07Pxbn0)

What can emerging biomarkers reveal about ALS biology? Join our upcoming webinar to learn how ultrasensitive multiplex proteomics is helping researchers uncover molecular signatures of neurodegeneration, inflammation, and disease progression. Register: na2.hubs.ly/H07D5d40

🔬 Have an immune-focused research project in mind? Apply for the NULISA Immunology Grant Program. Four projects will be selected to receive access to the NULISAseq™ Immune 340 Panel through our Technology Access Program (TAP). Apply by Oct 15: na2.hubs.ly/H07C0D_0

Join Caroline Chan, PhD (Alamar Biosciences) and Katharina Stracke, PhD (GeneWorks) for a webinar exploring how the NULISAseq™ Neuro 220 Panel is advancing neurological disease and biomarker research.   👉 Register here: na2.hubs.ly/H07y7vH0

In our latest Biomarker Edge blog, Alamar CSO Stephen Williams, MD, PhD, explores why amyloid alone doesn’t tell the whole Alzheimer’s story—and how direct measurement of eMTBR-Tau could help address a critical gap in blood-based Alzheimer’s research. 🔗 na2.hubs.ly/H07xrJl0

We're excited to welcome Panomics Biosciences to the Alamar Certified Service Provider network! Researchers can now access NULISA™ precision proteomics services through Panomics Biosciences in Australia.   Learn more about Panomics Biosciences: na2.hubs.ly/H07sSXD0

We’re excited to welcome Infinity Scope Multi-Omics to the Alamar Certified Service Provider (CSP) network!    Learn more about Infinity Scope Multi-Omics: na2.hubs.ly/H07njfJ0 Explore our Certified Service Provider network: na2.hubs.ly/H07nj2G0

🚀 Applications are open for the NULISA Immunology Grant Program! Four projects will receive access to the NULISAseq™ Immune 340 Panel, our newest panel for profiling ~340 key immune proteins with attomolar sensitivity from just 25 µL of sample. 🔗: na2.hubs.ly/H07gWX60

We’re pleased to welcome PBL Assay Science to the Alamar CSP network! With 30+ years of immunoassay and biomarker expertise, PBL Assay Science will expand access to NULISA™ precision proteomics.   Learn more about PBL Assay Science: na2.hubs.ly/H078b-t0

🚀 A major step forward for neurodegenerative disease research. Our expanded collaboration with ADDI and Gates Ventures adds 86,000 samples to a growing dataset expected to surpass 140,000 samples by 2027.   🔗Read the release: na2.hubs.ly/H075clq0

The NULISAseq™ Immune 340 Panel is now available! Download the data sheet to explore the panel content, assay performance, and technical specifications that power deeper immune profiling.   Download: na2.hubs.ly/H06Y1g-0

🚀 Introducing the NULISAseq™ Immune 340 Panel Measure ~340 immune proteins with attomolar sensitivity from a single plasma or serum sample for comprehensive immune profiling in a single assay. Learn more: na2.hubs.ly/H06X0pp0

We're pleased to welcome Sequanta Technologies to the Alamar Certified Service Provider network. With #NULISA technology, they're expanding access to ultra-sensitive, high-plex proteomics for biomarker discovery and translational research.   Learn more: na2.hubs.ly/H06R6dD0

This #WorldBrainDay, we're inspired by the progress being made in neuro research. From blood-based biomarkers to deeper insights into disease biology, new technologies are helping researchers expand what's possible in the study of brain health and neurodegenerative disease.

We're proud to highlight our partnership with Guilford Street Laboratories, an Alamar Biosciences Certified Service Provider (CSP). Learn more about our CSP program: na2.hubs.ly/H06P5y40

Wrapping up an incredible #AAIC2026. From our Product Theater with Dr. Thomas Karikari and Dr. Steve Williams to 140+ scientific presentations featuring #NULISA data, the conversations, collaborations, and science shared this week will continue to inspire what's next.

Day 3 at #AAIC26 ✅ From last night's networking event, In Navis Veritas, aboard the Cutty Sark, to today's Beyond pTau217 product theater, the last 24 hours have been packed with great discussions and new insights on Alzheimer's research. #Alzheimers #PrecisionProteomics

At #AAIC2026, one message is clear: Alzheimer's disease can't be understood with a single biomarker. Alamar CSO Steve Williams shares why multiplex biomarker profiling and blood-based testing are becoming critical for disease staging, clinical trials, and precision medicine.

AAIC Day 2 ✅ More great science, more great conversations. Excited to see growing momentum around blood-based biomarkers and proteomics in Alzheimer's research. Visit us at Booth 530 and please join our Product Theater on Tuesday, July 14, 1:20-2:00pm! #AAIC26 #Alzheimers

Alamar is partnering with Washington University, University of Wisconsin, and Indiana University to create a national proteomics resource for ADRD research. Profiling ~21,000 plasma samples from 10,000 participants. Read more: na2.hubs.ly/H06C87X0

AAIC Day 1 ✅ The highlight? The conversations. Thanks to the researchers, collaborators, and new connections who stopped by Booth 530 today. We're excited to see the momentum behind proteomics in Alzheimer's research. #AAIC26 #Alzheimers

We’re proud to welcome Bredis Healthcare as our newest CSP! Bredis delivers ultrasensitive immunoassay and proteomics services under GCLP and ICH standards in a dedicated cleanroom laboratory to advance biomarker research. Explore our CSPs: na2.hubs.ly/H06xWy10

🎉 Another FIRST for Alamar! We've launched the first commercial multiplexed immunoassay for eMTBR-Tau. Available in the NULISAseq™ Neuro 220 Panel and through TAP. See the data at AAIC 2026 in London, July 14. Read the release: na2.hubs.ly/H06wcyj0

A warm welcome to our Summer 2026 Interns! 🌟 We're excited to have you join us for a summer of innovation, collaboration, and growth. We can't wait to see the impact you'll make as we advance precision proteomics. Welcome to the team!

Join Alamar Biosciences at #AAIC26! Visit Booth 530 to see how ultra-sensitive precision proteomics is advancing biomarker discovery and translational research in Alzheimer's and other neurodegenerative diseases. 👉 Learn more: na2.hubs.ly/H06kpb80

We're excited to be at the Singapore Neuroscience Association Meeting as a Platinum Sponsor. Join Caroline Chan, PhD, as she presents how NULISA enables automated, ultra-sensitive biomarker profiling from biofluid samples. Thank you to Genomax Technologies for their partnership.

Join us at T21RS as Charlie Grieser, VP, Business Development – Population Health at Alamar, presents how ultra-sensitive biomarker profiling is providing new insights into AD progression and neuroinflammatory changes in Down syndrome.   👉: na2.hubs.ly/H069fHK0

Big news! Paris Brain&Mind is now the first European Center of Excellence for Alamar Biosciences. Together, we're accelerating the future of clinical proteomics through early access to next-gen NULISA assays, NULISA expert centers, and emerging bioinformatics pipelines.

This June, we recognize Alzheimer’s & Brain Health Awareness Month. At Alamar Biosciences, we empower researchers with ultra-sensitive proteomics like NULISA™ to advance biomarker discovery and deepen our understanding of neurodegenerative disease. #EndAlz #PrecisionProteomics

The NULISA™ DBS Extraction Kit streamlines protein extraction from DBS and DPS with a standardized, scalable workflow. Learn how it supports sensitive proteomic analysis and enables longitudinal, decentralized, and large-scale studies. 🔗 Download: na2.hubs.ly/H060tNX0

Join us at #FOCIS2026 this week to explore how ultra-sensitive proteomics is advancing immunology research. Don't miss presentations from Dr. Holden Maecker (Stanford) and Dr. Hayeun Ji (Alamar). Visit Booth 15 to connect with our team. Learn more: na2.hubs.ly/H060FBX0

Unlock high-quality proteomic data from dried blood and plasma spots. The NULISA™ DBS Extraction Kit enables standardized protein recovery from DBS and DPS samples collected across leading microsampling platforms.   Learn more: na2.hubs.ly/H05Y_nl0

Join us at the 2026 FOCIS Annual Meeting and discover how ultra-sensitive NULISA™ proteomics is helping researchers unlock deeper insights into immune biology.   Learn more: na2.hubs.ly/H05WTKW0

🩸Meet the NULISA™ DBS Extraction Kit Turn DBS/DPS microsamples into high-quality, analysis-ready specimens with a standardized, high-throughput workflow—enabling remote and longitudinal study designs. Learn more: na2.hubs.ly/H05T1Vn0 Read release: na2.hubs.ly/H05T4Gm0

Multiple sclerosis is a complex disease that demands earlier detection and more precise monitoring. We're proud to support MS researchers with ultra-sensitive proteomics tools that help uncover critical biomarkers. #WorldMSDay #Proteomics

Join Alamar Biosciences at the 7th World Parkinson's Disease Congress as the global Parkinson’s disease community comes together to explore the latest breakthroughs in PD research, biomarker discovery, and emerging therapeutics. Learn more: na2.hubs.ly/H05J0lD0

Don’t miss the 2026 Summit Advancing TDP-43 Biomarkers this Thursday. Virtual registration closes soon. Join leaders in neurodegeneration research as they discuss the latest advances in TDP-43 biomarker discovery and ADRD research. Register virtually: na2.hubs.ly/H05BhT40

Join us live from Amsterdam UMC on May 21 as researchers discuss ultra-sensitive proteomics and biomarker discovery in dementia & MS - with live online access available. Featuring speakers from AUMC, DZNE, UCL, HKUST & Barcelonaβeta/Lund. 👉 Register: na2.hubs.ly/H05kGNX0

📍 We’ll be at XXXIV AINI Congress in Rome! Learn how ultra-sensitive, multiplex proteomics can reveal biomarkers that refine MS phenotyping and biology in our speaker session with Anna Wojdala, PhD (Amsterdam UMC). 👉 na2.hubs.ly/H05cfJj0

🧬 International Day of Immunology Our ultra-sensitive NULISA technologies help researchers measure low-abundance biomarkers and uncover the biology driving disease. We're proud to support the research advancing the boundaries of immunology. #InternationalDayofImmunology

Happening this week, CSI brings together researchers advancing immunology. See how NULISA™ enables ultra-sensitive, multiplex protein analysis for low-abundance biomarkers and deeper insights. Visit our table to learn more.

Join our webinar with Labroots featuring Dr. Steve Williams, CSO at Alamar Biosciences, to learn how NULISA™ enables ultra-sensitive, multiplex detection of low-abundance protein biomarkers from small blood samples. Register now: na2.hubs.ly/H053N8F0

The past week marked an important milestone for Alamar. Our focus remains the same: powering precision proteomics to enable earlier disease detection. We’re grateful to our community and energized for what’s ahead. #NasdaqListed $ALMR

🚨 Only two weeks left to apply for the Parkinson’s Disease Grant Program. Apply by April 30, 2026, for a chance to receive one of 3 awards, including analysis of 86 samples using the NULISAseq™ Neuro 220 Panel. 🔗 Apply now: na2.hubs.ly/H04Vxq_0